Alzheimer's Disease
Page 1 • 2 itemsGlobal Alzheimer's disease market intelligence for pharma BD, investors & analysts. Track drug development, clinical trials & regulatory updates.
AC Immune Advances ACI-24 Alzheimer's Trial to Final Cohort, Initiates ACI-19764 Phase 1 Study
AC Immune progresses ACI-24 Alzheimer's treatment to final trial phase while starting new brain-penetrant NLRP3 inhibitor study in Q1 2026 update.
AC Immune Initiates Final Cohort in Phase 1b/2 ABATE Trial for Anti-Abeta Alzheimer's Treatment
AC Immune begins final patient cohort in ABATE trial testing anti-Abeta immunotherapy for Alzheimer's disease, triggering $12M milestone payment.